NCT07679347尚未招募不适用
Safety and Performance Evaluation of the SAVA Continuous Glucose Monitor for Effective Glucose Detection
SAVA Technologies Ltd.0 个研究点目标入组 20 人开始时间: 2026年8月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 主要终点
- Paired Sensor-Venous Blood Glucose Readings
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and performance of the SAVA Continuous Glucose Monitor across glucose ranges over a period of 15-day wear in adults over 18 years of age with Type 1 Diabetes. This is a pilot study, so the main purposes are to collect preliminary data for future studies, assess comfort and safety, and explore the accuracy of the CGM against references and benchmarks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant is willing and able to give informed consent to participate in the study.
- •The participant is at least 18 years of age at the time of enrolment.
- •The participant has a clinical diagnosis of Type 1 diabetes, with 7% < HbA1C < 10% within the last 6 months, for a minimum of 6 months duration prior to enrolment, as determined by a medical record by an individual qualified to make a medical diagnosis, and is using insulin (either by an insulin pump, subcutaneous injections, and/or inhaled insulin) for at least 6 months prior to enrolment.
- •If participant is using noninsulin glucose-lowering medications (such as SGLT2I Inhibitor, Metformin, or other), dose has been stable for at least 2 weeks prior to screening.
- •The participant body weight is at least 110 pounds, in accordance with U.S. Department of Health and Human Services guidance for blood collection.
- •The participant has adequate venous access as assessed by an investigator or appropriate centre staff.
- •The participant is available to attend all three up to 8-hour, clinically supervised, in-clinic sessions and to have multiple venous and capillary blood samples collected.
- •The participant agrees to not consume Vitamin C for the duration of the study.
- •The participant is prepared to record details related to their participation (e.g. meals, finger prick times, device incidents, comfort) daily.
- •The participant is prepared to wear up to three blinded investigational devices, and one unblinded investigational device for 15 days.
- •In the investigators' opinion, are suitable for participation in the study.
- •The participant is able to read and understand English.
- •The participant is willing to return the research devices at the end of the study.
- •The participant is willing to manage diabetes with insulin during study visits as they would do otherwise.
- •The participant can commit to not getting the CGMs wet for the first 12 hours after application, such as by showering or swimming.
排除标准
- •The participant gave birth within the last 6 months, is pregnant, is trying to conceive or is not willing and able to practice birth control during the study duration.
- •The participant has serious concomitant disorders or diseases (e.g. history of hypoglycaemia with unawareness requiring third party assistance, coagulation disorders) that would compromise the safety of the participant or their ability to complete the study, at the discretion of the Investigator.
- •The participant has had a recent cardiovascular event or major surgery in the last 6 months that would compromise the safety of the participant or their ability to complete the study, at the discretion of the Investigator.
- •The participant has been admitted to the hospital with Diabetic Ketoacidosis in the last 6 months prior to enrolment.
- •The participant has donated more than 500mL of blood in the past 4 weeks.
- •The participant has a blood haemoglobin (Hb) that is 10% or more below the normal reference range for men and women, at the discretion of the Investigator.
- •Current use of sulfonylurea medications.
- •Current use of GLP-1 Receptor Agonist medications.
- •The participant has an implanted medical device such as a pacemaker or an implantable cardioverter-defibrillator (ICD).
- •The participant has multiple tattoos, scars, active skin condition or wound, or significant dermatitis overlying the skin where devices are likely to be placed.
- •The participant has a known allergy or sensitivity to skin adhesives or sensor materials.
- •The participant is taking part in another interventional clinical study requiring blood sampling, an investigational drug or device during the 15-day wear period of this study.
- •The participant is not willing to suspend their hybrid closed loop (Automated Insulin Delivery) system during the clinic sampling session.
- •The participant has any X-ray or MRI scheduled at any time during the participation of the study.
- •Any other reason which, in the investigator's opinion, would compromise participant safety or data integrity.
研究组 & 干预措施
CGM Arm
Experimental
干预措施: CGM Devices (Device)
结局指标
主要结局
Paired Sensor-Venous Blood Glucose Readings
时间窗: For the duration of time the participant is wearing the CGM device (Day 0 to Day 14; up to 15 days)
The primary outcome is at least 98% of all paired sensor-venous blood glucose reference readings fall within the clinically acceptable Zones A and B of the Clarke Error Grid.
次要结局
- Assessment of comfort associated with devices at insertion and removal(At device application (Day 0) and removal (up to Day 14))
- Assessment of duration of pain associated with devices at insertion and removal(At device application (Day 0) and removal (up to Day 14))
- Evaluation of skin response at device wear sites(At device application (Day 0) and removal (up to Day 14))
- Characterisation of the safety profile of the SAVA CGMs(Up to 15 days (Day 14))
- Description of SAVA CGM clinical safety profile(Up to 15 days (Day 14))
研究者
相似试验
招募中
Unknown
A study in participants who requires facial improvement through dermal fillerCTRI/2025/01/078955Biotech vision care pvt ltd85
尚未招募
Unknown
Post-Market Clinical follow-up study to evaluate safety and performance of Altius Buechel Pappas Primary Total Knee Replacement SystemCTRI/2025/04/085046TTK Healthcare Ltd (Ortho Division)200
招募中
1 期
Safety and Efficacy of GL-2045 in Patients With Immune ThrombocytopeniaImmune ThrombocytopeniaNCT07605845Gliknik Inc.42
尚未招募
Unknown
A Clinical Study Assessing the Efficacy of Sarcoboost Supplementation in Enhancing Physical Performance, Respiratory Muscle Strength, and Health-Related Quality of Life in Patients With COPD-Related SarcopeniaCTRI/2025/12/098792Meghmani Lifesciences Limited,500
招募中
1 期
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)2022-502831-20-00Technische Universitat Dresden16